A Prospective, Multicentre Phase II Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS)
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary) ; Lenvatinib (Primary)
- Indications Bone metastases; Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms LENVOS
- 26 Aug 2019 Status changed from not yet recruiting to recruiting.
- 05 Feb 2019 Planned initiation date changed from 15 Dec 2018 to 31 Jan 2019.
- 15 Nov 2018 New trial record